Cancer-associated surface lipid

Cancer-associated surface lipids are a heterogeneous group of lipid molecules, including phospholipids, sphingolipids, and glycolipids, that exhibit altered expression or localization on the plasma membrane of malignant cells (Birge et al., 2016) [1]. In healthy cells, lipids like phosphatidylserine (PS) are strictly maintained on the inner leaflet of the membrane, but in the tumor microenvironment, they are frequently externalized to the outer leaflet, where they act as potent immunosuppressive signals (Belizaire & Uger, 2017) [4]. Additionally, complex glycolipids such as gangliosides (e.g., GD2, GD3) are often overexpressed on the surface of neuroectodermal tumors, contributing to cell-cell adhesion and signal transduction (Cheung & Dyer, 2013) [2]. These lipids are attractive therapeutic targets because their differential exposure or high density on tumor cells provides a degree of selectivity for monoclonal antibodies and other targeted agents (NCI, 2023) [3]. Drugs like dinutuximab and naxitamab target GD2 to treat neuroblastoma, while agents like bavituximab have been developed to target PS and reverse its immunosuppressive effects (Birge et al., 2016) [1]. Targeting these lipids can induce direct tumor cell killing through immune-mediated mechanisms like antibody-dependent cellular cytotoxicity (ADCC) or by modulating the immune landscape of the tumor (Belizaire & Uger, 2017) [4].

Other names

Tumor-associated lipidTumor-specific lipidCancer-associated glycolipidSurface-exposed phospholipidTumor-associated ganglioside

Therapeutic agents, primarily monoclonal antibodies, bind to specific lipids that are either overexpressed or aberrantly localized on the outer leaflet of the tumor cell plasma membrane. This binding facilitates tumor cell destruction through immune-mediated pathways, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Cheung & Dyer, 2013) [2]. For targets like phosphatidylserine, the mechanism also involves blocking the "do not eat me" signaling that typically suppresses the innate immune response, thereby promoting an inflammatory, anti-tumor environment (Birge et al., 2016) [1].